We previously demonstrated that infection of CLL cells with modiWed vaccinia Ankara (MVA) expressing the costimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM) increased expression of these costimulatory molecules on the surface of CLL cells and thus augmented their antigen-presenting capability. Here, we evaluate the eVect of MVA-TRICOM-modiWed CLL cells on T cells. Following incubation with irradiated MVA-TRI-COM-modiWed CLL cells, allogeneic and autologous CD4 + and CD8 + T cells expressed signiWcantly higher levels of B7-1, ICAM-1, and LFA-3. We show that this increase was the result of physical acquisition from the antigen-presenting cells (APCs), and that puriWed T cells that acquired costimulatory molecules from MVA-TRICOM-modiWed CLL cells were able to stimulate the proliferation of untreated T cells. These results demonstrate for the Wrst time that T cells from CLL patients can acquire multiple costimulatory molecules from autologous CLL cells and can then act as APCs themselves. Given the immunodeWciencies characteristic of CLL, enhancing the antigen-presenting function of CLL cells and T cells simultaneously could be a distinct advantage in the eVort to elicit antitumor immune responses.
Introduction
Chronic lymphocytic leukemia (CLL) is a malignancy characterized by accumulation of clonal CD5 + B lymphocytes that are ineYcient in antigen presentation [7, 25] , largely due to an inadequate costimulatory capacity. The limited ability of CLL cells to present antigens to T cells is manifested as a failure to stimulate proliferation of both allogeneic and autologous T cells. CLL is also characterized by profound defects in the T-cell compartment, which are believed to increase the risk of infection and to hinder immune recognition and elimination of leukemic cells [2, 22] . It has been proposed that the distinctive phenotype and functional defects of T cells from CLL patients may result from T-cell interaction with the malignant B-cell clone [14] . Moreover, it has been demonstrated that contact with CLL cells induces several defects in healthy T cells in vitro [5] .
EVective stimulation of T cells by antigen-presenting cells (APCs) involves two signaling events. Signal 1 is induced by T-cell receptor (TCR) recognition of peptide-MHC complexes, and signal 2 is triggered by interaction of costimulatory molecules on the surface of the APC with speciWc ligand(s) on the T-cell surface [13] . To form tight conjugates between T cells and APCs, various cell surface molecules (TCR/CD3, peptide/MHC, CD28/B7, CD2/LFA-3, LFA-1/ICAM-1, among others) segregate into distinct regions or clusters, designated supramolecular activation clusters (SMACs) [16] that create an organized interface referred to as an immunological synapse [6] . It has been previously demonstrated that as a result of this Wrm coupling of T cell and APC, molecules can be transferred to the T cell from the surface of various APCs, including insect cells, dendritic cells, and tumor cell lines [1, 8-10, 20, 23] . Both CD4 + and CD8 + T cells have been shown to acquire peptide/ MHC complexes from the surface of APCs in an antigendependent manner [1, 8, 10, 20] . Following this molecular transfer, CD4 + T cells can induce proliferation of T cells with the same antigen speciWcity in a secondary culture [1] , whereas CD8 + T cells that have acquired peptide/MHC complexes become susceptible to fratricide killing by neighboring T cells [8] . In addition to peptide/MHC molecules, it has also been demonstrated that T cells can extract from the surface of APCs costimulatory molecules such as B7-1 and B7-2, and that this transfer can be mediated by either TCR-peptide/MHC interaction or CD28-B7 interaction [10, 20, 23] . Whereas activated T cells eYciently acquire B7 molecules via CD28 [10] , the level of B7-1 acquisition by naïve CD4 + T cells, with their lower expression of CD28, has been shown to be directly proportional to both the strength of signal 1 and the amount of B7-1 expressed on the surface of the APCs [20, 23] . Following acquisition of B7-1 and peptide/MHC complexes, the fates of naïve and eVector/memory CD4 + T cells appear to be diVerent. While naïve CD4 + T cells can act as APCs after acquisition, eVector/memory CD4 + T cells can undergo apoptosis in the presence of increased levels of signal 1 [17, 20, 27] .
We demonstrated in a previous report that in vitro infection of CLL cells with replication-defective modiWed vaccinia Ankara (MVA) engineered to express the human costimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM) increased expression of these costimulatory molecules on the surface of CLL cells and thus augmented the ability of the CLL cells to stimulate proliferation of allogeneic and autologous T cells [18] . Importantly, all three costimulatory molecules were shown to contribute to the improvement of antigen-presenting capacity. Furthermore, cytotoxic T lymphocytes generated in vitro by stimulation of autologous T cells with MVA-TRI-COM-modiWed CLL cells showed cytotoxicity against unmodiWed CLL cells [18] . To better understand the ability of MVA-TRICOM-modiWed CLL cells to elicit strong Tcell proliferation-taking into account that interaction with CLL cells can induce profound phenotypic alterations in T cells-we analyzed the phenotype of allogeneic and autologous T cells after contact with CLL cells that were unmodiWed or modiWed by infection with MVA-TRICOM. Our results demonstrate that after a brief contact with MVA-TRICOM-modiWed CLL cells, allogeneic and autologous
CD4
+ and CD8 + T cells express signiWcantly higher levels of the costimulatory molecules B7-1 and ICAM-1 (and to a lesser extent LFA-3) on their cell surface, compared to T cells that have been in contact with unmodiWed CLL cells. This Wnding is demonstrably the result of physical acquisition of costimulatory molecules from the APCs and not of endogenous upregulation of each molecule. Moreover, we demonstrate that puriWed T cells that have acquired costimulatory molecules through brief contact with MVA-TRICOM-modiWed CLL cells have the ability to then stimulate the proliferation of untreated T cells, and therefore, have acquired the ability to act as APCs. These results show for the Wrst time that T cells from CLL patients can acquire costimulatory molecules from autologous CLL cells and can then act as APCs themselves. While all previous studies demonstrated T cell acquisition of costimulatory molecules from a range of APCs including insect cells, dendritic cells, or tumor cell lines, to our knowledge, these studies provide the Wrst direct demonstration that T cells can acquire costimulatory molecules from primary tumor cells. Finally, these results show the novel Wnding that APCs which exhibit high expression of B7-1, ICAM-1, and LFA-3 can transfer all three costimulatory molecules to T cells. We hypothesize that T cell acquisition of costimulatory function after a brief contact with TRICOM-modiWed CLL cells might provide an advantage in eliciting an eVective immune response against the tumor cells.
Materials and methods

PBMCs from CLL patients and healthy donors
Peripheral blood was collected at the University of Pittsburgh Cancer Institute from patients diagnosed with CLL, after informed consent was obtained and following approval by the University of Pittsburgh Institutional Review Board. Peripheral blood was collected at NIH from healthy donors, after informed consent was obtained and following approval by the NIH Institutional Review Board. Peripheral blood mononuclear cells (PBMCs) were isolated as previously described [18] . Unless otherwise noted, cells were cultured in RPMI 1640 medium (Mediatech, Inc., Herndon, VA) supplemented with 2 mM glutamine, 1 £ antibiotic/antimycotic solution (Mediatech, Inc.), and 10% human AB serum (Gemini Bio-Products, West Sacramento, CA).
MVA viruses
A replication-defective MVA vector expressing genes encoding for the human B7-1, ICAM-1, and LFA-3 costimulatory molecules (designated TRICOM) was used. Wild-type (WT) MVA virus was used as a control vector.
Both viruses were kindly provided by Therion Biologics (Cambridge, MA).
ModiWcation of CLL cells with MVA viruses
T cells were removed from PBMCs from patients with CLL by anti-CD4 and anti-CD8 microbeads (Miltenyi Biotec, Auburn, CA). The remaining CLL cells were resuspended at 4 £ 10 6 cells/mL in Opti-MEM (Invitrogen, Carlsbad, CA), plated at 2 £ 10 6 cells/well (in 0.5 mL) on a 24-well plate, and modiWed with Wve plaque-forming units/cell of MVA virus (multiplicity of infection = 5) for 1 h at 37°C. Following modiWcation, 1.5 mL of prewarmed medium containing 10% human AB serum was added to the cells, and cells were cultured for an additional 24 h.
Flow cytometry CD19-FITC, CD19-PE-Cy5, CD4-FITC, CD4-APC-Cy7, CD8-APC-Cy7, CD8-PE-Cy5, CD8-PE-Cy7, CD3-PECy7, B7-1-PE, ICAM-1-PE, LFA-3-PE, and CD40-APC were purchased from BD Biosciences Pharmingen (San Diego, CA). HLA Class II (DQ, DP, DR)-PE was purchased from Serotec, Inc. (Raleigh, NC).
Mixed lymphocyte reaction (MLR)
Allogeneic MLR and autologous lymphocyte proliferation assays were conducted as previously described [18] .
Acquisition of costimulatory molecules by T cells T cells were negatively isolated from PBMCs of healthy donors by using the Pan T Cell Isolation Kit (Miltenyi Biotec). T cells were negatively isolated from PBMCs of CLL patients by depletion of CLL cells using anti-CD19 microbeads, followed by the Pan T Cell Isolation Kit (Miltenyi Biotec). PuriWed T cells from either healthy donors (allogeneic) or CLL patients (autologous) were cocultured with irradiated (75 Gy) CLL cells at a 5:1 ratio for 4 h at 37°C. CLL cells were either unmodiWed or modiWed with MVA vectors as described above.
In experiments with cycloheximide (CHX) treatment, T cells were pretreated with 20 g/mL CHX (Sigma-Aldrich, St. Louis, MO) for 2 h at 37°C, then incubated with irradiated CLL cells for 4 h in the presence of the same concentration of CHX. As a control, T cells that were pretreated for 2 h with CHX were activated with 5 ng/mL phorbol myristate acetate (PMA) and 1 M ionomycin for 4 h in the continued presence of CHX. For antibody (Ab) blocking experiments, CLL cells were pretreated with puriWed Ab to human B7-1, ICAM-1, or LFA-3 (or control mouse IgG1; Serotec, Inc.) at a concentration of 20 g/mL for 1 h at 37°C, then incubated with T cells for 4 h in the presence of the same concentration of Ab. Alternatively, T cells were pretreated with puriWed Ab to human CD28, CD11a, or CD2 (or control mouse IgG1; Serotec, Inc.) at a concentration of 20 g/mL for 1 h at 37°C, then incubated with CLL cells for 4 h in the presence of the same concentration of Ab.
RT-PCR
T cells were puriWed after 4-h acquisition by negative selection with two rounds of anti-CD19 microbeads (Miltenyi Biotec), and RNA was isolated using the RNeasy Kit (Qiagen, Valencia, CA). RT-PCR was performed on 0.04 g RNA using the Titanium One-Step RT-PCR Kit (Clontech, Mountain View, CA) according to the manufacturer's suggested protocol, using 30 cycles of denaturation (94°C, 30 s), annealing (65°C, 30 s), and polymerization (68°C, 1 min). Products (5 L) were reampliWed using the Platinum PCR SuperMix (Invitrogen) by a Wrst denaturation at 94°C for 5 min, 30 cycles of denaturation (94°C, 30 s), annealing (55°C, 30 s), and polymerization (72°C, 1 min), followed by an extension step at 72°C for 7 min. The following primers were used: B7-1-F 5Ј GAC CCT AAG CAT CTG AAG CCA TG 3Ј, B7-1-R 5Ј TGA TCC CCA CGA TCC ATG TAT C 3Ј, CD3 -F 5Ј GTG TCA TTC TCA CTG CCT TGT TCC 3Ј, CD3 -R 5Ј TTC AGT GGC TGA GAA GAG TGA ACC 3Ј, CD19-F 5Ј TCA CCG TGG CAA CCT GAC CAT G 3Ј, and CD19-R 5Ј GAG ACA GCA CGT TCC CGT ACT G 3Ј. As a positive control, Epstein-Barr virus (EBV)-transformed B cells were diluted 1:100 in 1 £ 10 7 T cells from a healthy donor. All PCR products were resolved on 1.2% agarose E-Gels (Invitrogen); expected product sizes for B7-1, CD3, and CD19 were 1 kb, 468 bp, and 278 bp, respectively.
Anti-CD3-mediated proliferation assay
For proliferation assays with T cells from healthy donors, T cells were puriWed after 2-h acquisition by negative selection with two rounds of anti-CD19 microbeads (Miltenyi Biotec). Untreated T cells from the same healthy donor (5 £ 10 4 cells/well) were cocultured with irradiated (50 Gy) T cells from acquisition (5 £ 10 4 cells/well) in triplicate wells of 96-well round-bottom culture plates precoated with 0.01 g/mL anti-CD3 Ab (BD Biosciences Pharmingen). For proliferation assays with T cells from CLL patients, T cells from CLL patients were puriWed after 2-h acquisition by negative selection with three rounds of anti-CD19 microbeads (Miltenyi Biotec). Untreated T cells from a CLL patient (2.5 £ 10 4 cells/well) were cocultured with irradiated (50 Gy) T cells from acquisition (2.5 £ 10 Biosciences Pharmingen). For all proliferation assays, cells were cultured for 6 days and pulsed with 3 H-thymidine (1 Ci/well) for the Wnal 16 h before harvesting. Stimulation index was calculated as average cpm (T cells + irradiated T cells)/average cpm (T cells alone).
Results
Phenotypic modiWcation of allogeneic T cells from healthy donors following incubation with MVA-TRICOM-modiWed CLL cells
Infection of CLL cells with MVA-TRICOM was previously shown to increase expression of the costimulatory molecules B7-1, ICAM-1, and LFA-3 on their cell surface, resulting in an augmentation of their antigen-presenting ability [18] . In accordance with these previous observations, we show here that proliferation of T cells from four healthy donors was signiWcantly enhanced after contact with allogeneic MVA-TRICOM-modiWed CLL cells, compared to contact with unmodiWed or MVA-WT-modiWed CLL cells (Fig. 1a) . Similarly, proliferation of T cells from six CLL patients was increased following contact with autologous MVA-TRICOM-modiWed CLL cells (Fig. 1b) . We then examined the phenotype of T cells that had been incubated with MVA-TRICOM-modiWed CLL cells. After allogeneic T cells from healthy donors were incubated with irradiated MVA-TRICOM-modiWed CLL cells for 4 h at 37°C, CD4 + and CD8 + T cells exhibited an increase in the percentage of cells with surface expression of B7-1 and ICAM-1; an increase in LFA-3 was evident from mean Xuorescent intensity (MFI) of expression ( Fig. 2a, b , showing results for three healthy donors assayed). As a control, T cells incubated with MVA-WT-modiWed CLL cells showed expression levels of B7-1, ICAM-1, and LFA-3 that were comparable to levels in untreated T cells (Fig. 2a,  b) . Comparable results were obtained from six healthy donors assayed (following incubation with MVA-TRI-COM-modiWed CLL cells from six CLL patients). T cells from all of the healthy donors exhibited an increase in surface expression of B7-1 (by percentage of expression), ICAM-1 (by percentage and/or MFI of expression), and LFA-3 (by MFI of expression). However, the magnitude of the increase varied from donor to donor, as can be seen for three of the six healthy donors assayed in Fig. 2a, b . Increased expression of HLA class II molecules was also seen in allogeneic CD4 + and CD8 + T cells after contact with MVA-TRICOM-modiWed CLL cells (data not shown). HLA class I (HLA-A,B,C) expression on allogeneic T cells was not changed by incubation with MVA-TRICOM-modiWed CLL cells, nor was HLA-A2 surface expression evident on allogeneic HLA-A2 ¡ T cells after contact with HLA-A2 + MVA-TRICOM-modiWed CLL cells (data not shown). To rule out the possibility that a tight interaction between T cells and TRICOM-expressing CLL cells had skewed the Xow cytometry results, the samples were simultaneously stained for CD19 expression. Results showed ·0.3% expression of CD19, thus excluding the possibility of B-cell contamination within the T-cell fraction. These results demonstrate that a brief incubation with MVA-TRI-COM-modiWed CLL cells results in phenotypic modiWcation of allogeneic T cells from healthy donors.
EVect of CHX treatment on expression of costimulatory molecules by allogeneic T cells from healthy donors
To determine whether the increase in costimulatory molecules on allogeneic T cells after incubation with MVA-TRI-COM-modiWed CLL cells was due to upregulation of endogenous expression by the T cells or to acquisition from the CLL cells, allogeneic T cells were incubated with CHX before and during incubation with MVA-TRICOM-modiWed CLL cells and subsequently analyzed for expression of B7-1, + and CD8 + T cells from healthy donors with MVA-TRICOM-modiWed CLL cells, levels of surface expression of B7-1, ICAM-1, and HLA class II on CHX-treated T cells (in which protein synthesis is abrogated) were equal to levels seen on untreated T cells (Fig. 2c, d , showing results for three healthy donors assayed). CHX-treated T cells activated during the 4-h incubation with PMA and ionomycin did not exhibit upregulation of CD69 (74.3% of untreated T cells vs. 12.8% of CHX-treated T cells), demonstrating that CHX inhibited new protein synthesis. These Wndings demonstrate that the increase in costimulatory and HLA class II molecules on allogeneic T cells is due to acquisition from the MVA-TRICOM-modiWed CLL cells.
EVect of Ab blocking on expression of costimulatory molecules by allogeneic T cells from healthy donors
We analyzed the respective contributions of B7-1, ICAM-1, and LFA-3 to the acquisition of costimulatory molecules by T cells by treating MVA-TRICOM-modiWed CLL cells with blocking Ab to each costimulatory molecule before and during incubation with allogeneic T cells from healthy donors. Blocking of LFA-3 on MVA-TRICOM-modiWed CLL cells produced the most striking eVect on acquisition by allogeneic T cells, decreasing the acquisition of LFA-3, as evidenced by MFI (data not shown), as well as B7-1, ICAM-1, and HLA class II molecules (Table 1 ). In contrast, blocking of ICAM-1 did not signiWcantly impair the acquisition of any of the molecules, while anti-B7-1 Ab signiWcantly blocked the acquisition of B7-1 by CD4 + and CD8 + T cells (Table 1) .
APC function of T cells from healthy donors that have acquired costimulatory molecules from MVA-TRICOMmodiWed CLL cells
We examined whether T cells from healthy donors that had acquired costimulatory molecules from MVA-TRICOMmodiWed CLL cells could function as APCs to untreated T cells. T cells from healthy donors were cultured with either unmodiWed, MVA-WT-modiWed, or MVA-TRICOM-mod- (Fig. 3c, d) . CHX-treated autologous T cells also showed enhanced surface expression of the three costimulatory molecules, indicating that the increase was due to acquisition from the MVA-TRICOM-modiWed CLL cells and not to endogenous expression by the T cells (Table 2 , showing results for one representative donor of two CLL patients assayed). These results demonstrate that autologous T cells from CLL patients acquire costimulatory molecules following a brief incubation with MVA-TRICOM-modiWed CLL cells.
As observed with allogeneic T cells, treatment of MVA-TRICOM-modiWed CLL cells with blocking Ab to B7-1 signiWcantly decreased acquisition of B7-1 by autologous T cells from CLL patients; for a representative donor, acquisition of B7-1 by CD4 + T cells was reduced from 28.5% for the isotype control to 12.9% with anti-B7-1 Ab ( Figure S2A of Electronic Supplementary Material). Further, treatment 
Analysis of B7-1 mRNA expression in autologous T cells from CLL patients
Of the three costimulatory molecules examined in this study, B7-1 alone is negligibly expressed on untreated T cells. To further demonstrate that T cells were acquiring B7-1 from MVA-TRICOM-modiWed CLL cells rather than upregulating endogenous expression, we performed RT-PCR analysis for B7-1, the T-cell marker CD3, and the Bcell marker CD19. Autologous T cells from CLL patients were incubated with irradiated MVA-TRICOM-modiWed CLL cells for 4 h at 37°C, puriWed by depletion of B cells, and subjected to RNA isolation. Autologous T cells exhibited increased surface expression of B7-1 by Xow cytometry following incubation with TRICOM-expressing CLL cells (Fig. 4a) . However, no ampliWcation of B7-1 was observed by RT-PCR in unmodiWed T cells or T cells incubated with MVA-TRICOM-modiWed CLL cells, while CD3 was uniformly ampliWed in all samples (Fig. 4b) . To establish the sensitivity of the RT-PCR for B7-1, EBV-transformed B cells were diluted into T cells from a healthy donor prior to RNA isolation. The B7-1 message could be detected from 10,000 EBV-transformed B cells diluted in 1 £ 10 7 T cells (1:1,000) (data not shown). These results further demonstrate that the increase in surface expression of B7-1 on autologous T cells after incubation with MVA-TRICOM-modiWed CLL cells is not due to upregulation of endogenous B7-1, but rather to acquisition from the CLL cells. Because CD19 was not ampliWed from the puriWed T cells (data not shown), the results also indicate that after a 4-h incubation with MVA-TRICOM-modiWed CLL cells, puriWed T cells are free of contaminant CLL cells.
APC function of T cells from CLL patients that have acquired costimulatory molecules from MVA-TRICOMmodiWed CLL cells
We examined whether T cells from CLL patients that had acquired costimulatory molecules from MVA-TRICOM- modiWed CLL cells could function as APCs to untreated T cells. T cells from CLL patients were cultured with either unmodiWed, MVA-WT-modiWed, or MVA-TRICOM-modiWed irradiated CLL cells at a 5:1 ratio for 2 h at 37°C, after which the T cells were puriWed by depletion of B cells. As a control for possible CLL contamination, aliquots of the puriWed T cells were stained for CD19 and CD40; all groups exhibited ·0.5% expression of the B-cell markers (shown for T cells from acquisition with MVA-TRICOMmodiWed CLL cells from one representative patient in Fig. 4c) . The puriWed T cells from acquisition were irradiated and cocultured with untreated T cells from a CLL patient at a 1:1 ratio in a proliferation assay, on plates precoated with 0.01 g/mL anti-CD3 Ab as stimulant. T cells that had acquired costimulatory molecules from MVA-TRICOM-modiWed CLL cells induced anti-CD3-mediated proliferation of the eVector T cells (stimulation indexes of 4.9, 44.6 and 3.2 for three patients assayed; Fig. 4d ). T cells that had been incubated with unmodiWed or MVA-WTmodiWed CLL cells (and had not acquired costimulatory molecules) did not function as APCs in the proliferation assay (Fig. 4d) . Thus, T cells from CLL patients that had acquired costimulatory molecules from TRICOM-expressing CLL cells were capable of functioning as APCs to untreated T cells.
Discussion
Chronic lymphocytic leukemia is a disease in which both malignant B cells and nonmalignant T cells exhibit dysfunction. CLL cells show decreased expression of costimulatory molecules such as B7-1 and B7-2, resulting in an inability to provide an adequate signal 2, which is required for T-cell activation [2, 7, 25] . Equally important, T cells from CLL patients show an inverted CD4/CD8 ratio, altered cytokine production, and decreased mitogenic and allogeneic responses, despite their increased absolute numbers and enhanced expression of activation markers [2, 22] . Current therapies for CLL, including the nucleoside analog Xudarabine and the monoclonal Ab alemtuzumab, can further depress T cell-mediated immunity, thereby diminishing the potential for tumor control and increasing the risk of opportunistic infections [19] . Thus, there is substantial interest in developing CLL-speciWc immunotherapies that could limit tumor growth while boosting immune response.
We have previously demonstrated that modiWcation of CLL cells with MVA-TRICOM, a recombinant virus encoding B7-1, ICAM-1, and LFA-3, results in increased surface expression of these three costimulatory molecules, with concomitant augmentation of the antigen-presenting ability of the CLL cells [18] . We show here that both allogeneic and autologous CD4 + and CD8 + T cells exhibit higher levels of surface expression of B7-1, ICAM-1, and LFA-3 after a 4-h exposure to MVA-TRICOM-modiWed CLL cells. We also demonstrate that allogeneic CD4 + and CD8 + T cells exhibit higher levels of HLA class II, but not HLA class I, following a 4-h incubation with MVA-TRI-COM-modiWed CLL cells.
Protein synthesis inhibition experiments, and RT-PCR analysis in the case of B7-1, provided evidence that higher surface expression by T cells of the three costimulatory molecules and HLA class II was the result of physical acquisition from the CLL cells. These results are consistent with previous reports which show the transfer of B7 and ICAM-1 from APCs to T cells [10, 20, 23] , as well as the transfer of MHC class II from allogeneic APCs to human T cells [4, 24] . For ICAM-1 and LFA-3, which are more widely expressed by T cells prior to incubation with MVA-TRICOM-modiWed CLL cells, the possibility remains that the increased surface expression results from redistribution of pre-formed molecules within the T cell. Further experiments could more directly assess whether acquisition is occurring by utilizing CLL cells which are infected with MVA virus expressing GFP-tagged TRICOM molecules.
We also show by Ab-mediated blocking experiments that the acquisition of the three costimulatory molecules and HLA class II was mainly dependent on the interaction between LFA-3/CD2, while the interaction between ICAM-1/LFA-1 had a negligible eVect on acquisition. These results are consistent with previous reports in other cell types showing the importance of LFA-3 in the transfer of B7-1 and MHC class II from APCs to T cells [4, 24] . Acquisition of B7-1 was similarly abrogated by Ab blocking directed against B7-1 or the correspondent CD28 ligand, which is also in accordance with previous studies showing CD28-mediated absorption of B7 molecules by T cells [10] . The relative importance of these receptor/ligand pairs in the acquisition of costimulatory molecules may mirror their relative importance in forming and stabilizing the immunological synapse between T cell and APC. For instance, interaction between CD2 and LFA-3 is thought to form a complex with the same dimensions as the TCR-peptide/ MHC complex, which favors close membrane proximity and stabilizes the synapse by excluding larger molecules, such as CD43 and CD45, from the contact interface [15] . In contrast, the larger ICAM-1 molecule is excluded from the central SMAC and, perhaps because of this exclusion, appears to play no role in the T-cell acquisition process, except in those cases where T cells are absorbing molecules from exosome-like membrane vesicles shed from APCs [11] . Consistent with this observation, our results also indicate that transfer of costimulatory molecules from CLL cells to T cells is independent of membrane vesicles.
Acquired molecules have previously been shown to alter the function of T cells in vitro and in vivo. Zhou et al. demonstrated that naïve T cells can acquire B7-1/MHC molecules from professional APCs, and that these acquired molecules can sustain T-cell activation/proliferation in the absence of APCs [27] . It has also been shown that CD4 + and CD8 + T cells from HIV-infected individuals express increased levels of B7-1 and B7-2, which allow the T cells to act as APCs [12, 26] . Further, T cells from myeloma patients have been demonstrated to acquire B7 antigens, and this phenotype seems to be associated with stable disease [3] . We have shown here for the Wrst time that, after acquiring costimulatory molecules from MVA-TRICOMmodiWed CLL cells, T cells from CLL patients are capable of functioning in vitro as APCs to untreated T cells from CLL patients. T cells which acquired costimulatory molecules provided signal 2 to untreated T cells in an anti-CD3-mediated proliferation assay. To more closely mimic the situation in vivo, further experiments could assess the capacity of the modiWed T cells to stimulate an antigen-speciWc response against a recall antigen, for example by pulsing T cells which acquired costimulatory molecules with a peptide epitope from inXuenza virus. Previous studies from our laboratory have shown that CD4 + TCR-transgenic T cells which have acquired costimulatory molecules can eVectively stimulate antigen-speciWc proliferation and cytokine production [27] . Undale et al. also demonstrated that T cells which have acquired MHC class II can present peptide to antigen-speciWc CD4 + T cells [24] . While it is diYcult to deduce the implications of this acquisition in vivo, we speculate that T cells which acquire costimulatory molecules will amplify the immune stimulation induced by MVA-TRICOM-modiWed CLL cells used as a vaccine. UnmodiWed CLL cells express low levels of costimulatory molecules, and thus cannot provide a signal 2 adequate for T-cell activation. In vivo, circulating T cells that have contact with unmodiWed CLL cells will thus likely be activated only by signal 1, which could lead to anergy. However, T cells in vivo that acquire costimulatory capacity through contact with MVA-TRICOM-modiWed CLL cells administered via a vaccine may be able to deliver the missing signal 2 to those T cells activated by unmodiWed CLL cells, thereby enhancing immune response. We further showed that allogeneic T cells also acquire HLA class II from MVA-TRICOM-modiWed CLL cells, and other groups have previously shown that T cells can acquire entire peptide-MHC complexes from APCs [1, 8, 10, 20, 24] , suggesting the possibility that T cells following acquisition could deliver both signals 1 and 2 to activate leukemia-speciWc T cells. This phenomenon of acquisition of costimulatory molecules by T cells has previously been shown in murine models to have potentially important biologic implications. In the literature, naïve CD4 + T cells which acquired B7 stimulated the proliferation of untreated T cells [20, 27] , whereas memory CD4 + T cells which acquired B7 were more susceptible to apoptosis in vitro and in vivo, a susceptibility dependent on the strength of signal 1 [17, 20] . Also, in a previous report, CD8 + T cells which acquired peptide/MHC complexes became susceptible to fratricide killing by neighboring T cells [8] . Future experiments should be performed to clarify the distinction between eVects on naïve versus memory T cells.
This study thus further supports the rationale for the use of CLL cells modiWed ex vivo with MVA-TRICOM as a whole tumor-cell vaccine for the immunotherapy of CLL. Given the profound immune deWciencies characteristic of CLL, the ability to enhance the antigen-presenting function of CLL cells and T cells simultaneously could be a distinct advantage in the eVort to elicit an eVective immune response.
